These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14258688)

  • 1. [RESEARCH ON THE ANTIHEPARINIC ACTIVITY OF PHOSPHOLIPIDS. 3. ACTION OF BLOOD PLATELETS AND THEIR PHOSPHOLIPID SUBSTITUTES ON THE ANTITHROMBIN ACTIVITY OF HEPARIN].
    ASCARI E; BARBIERI U; GOBBI F
    Prog Med (Napoli); 1964 Sep; 20():593-6. PubMed ID: 14258688
    [No Abstract]   [Full Text] [Related]  

  • 2. [RESEARCH ON THE ANTIHEPARIN ACTIVITY OF PHOSPHOLIPIDS. II. ACTION OF PLATELETS AND THEIR PHOSPHOLIPID SUBSTITUTES ON PROACCELERIN INHIBITION BY HEPARIN].
    ASCARI E; BARBIERI U; GOBBI F
    Prog Med (Napoli); 1964 Sep; 20():580-3. PubMed ID: 14258160
    [No Abstract]   [Full Text] [Related]  

  • 3. [RESEARCH ON THE ANTIHEPARIN ACTIVITY OF PHOSPHOLIPIDS. I. ACTION OF BLOOD PLATELETS AND THEIR PHOSPHOLIPID SUBSTITUTES ON INHIBITION OF TROMBOPLASTIN FORMATION BY HEPARIN].
    ASCARI E; BARBIERI U; GOBBI F
    Prog Med (Napoli); 1964 Aug; 20():531-5. PubMed ID: 14256537
    [No Abstract]   [Full Text] [Related]  

  • 4. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A STABLE PHOSPHOLIPID REAGENT AS A THROMBOCYTE SUBSTITUTE IN COAGULATION ANALYSIS].
    FISCHER M
    Arzneimittelforschung; 1964 Dec; 14():1321-4. PubMed ID: 14341619
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXOGENOUS HEPARIN AND THE HEPARIN CO-FACTOR. EXPERIMENTAL AND CLINICAL STUDIES.
    OLSSON P
    Acta Chir Scand Suppl; 1963; 18():SUPPL319:1-37. PubMed ID: 14085709
    [No Abstract]   [Full Text] [Related]  

  • 8. THE EFFECT OF HEPARIN AND EPSILON-AMINOCAPROIC ACID ON THE COAGULATION IN HYPOTHERMIC DOGS.
    JOHANSSON BW; NILSSON IM
    Acta Physiol Scand; 1964 Mar; 60():267-77. PubMed ID: 14131840
    [No Abstract]   [Full Text] [Related]  

  • 9. HEPARIN AND SOME COAGULATION FACTORS IN EXPERIMENTAL BURN INJURIES.
    JOHANSSON SA
    Acta Chir Scand; 1964 Oct; 128():346-9. PubMed ID: 14211289
    [No Abstract]   [Full Text] [Related]  

  • 10. [Problem of the antiheparinic activity of the serum and blood platelets in persons treated with Pelentan].
    Cieslar P; Hermanský F
    Cas Lek Cesk; 1971 Sep; 110(36):833-6. PubMed ID: 5093693
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANTITHROMBIN ACTIVITY (HEPARIN CO-FACTOR) IN PLASMA AFTER MAJOR SURGERY IN HEPARINIZED PATIENTS.
    OLSSON P; VON FRANCKEN ; NORDSTROEM S
    Acta Chir Scand; 1964 Jun; 127():578-83. PubMed ID: 14175132
    [No Abstract]   [Full Text] [Related]  

  • 15. REQUIREMENT FOR CALCIUM IN THE THROMBOPLASTIN GENERATION TEST.
    GASTON LW; EVANGER AE
    J Lab Clin Med; 1964 Sep; 64():501-11. PubMed ID: 14215467
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of a new laboratory test to evaluate antithrombin resistance in plasma.
    Murata M; Takagi A; Suzuki A; Okuyama E; Takagi Y; Ando Y; Kato I; Nakamura Y; Murate T; Matsushita T; Saito H; Kojima T
    Thromb Res; 2014 Feb; 133(2):293-8. PubMed ID: 24325876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EFFECT OF ADENOSINE NUCLEOTIDES ON PLATELET AGGREGATION AND CLOTTING TIME.
    MUSTARD JF; HEGARDT B; ROWSELL HC; MACMILLAN RL
    J Lab Clin Med; 1964 Oct; 64():548-59. PubMed ID: 14233144
    [No Abstract]   [Full Text] [Related]  

  • 18. A COMPARISON OF THE EFFECT OF PLATELETS AND ERYTHROCYTES ON THE INHIBITORY ACTION OF BLOOD COAGULATION BY POLYBRENE AND HEPARIN.
    SHANBERGE JN; FURUTA S
    Thromb Diath Haemorrh; 1964 Oct; 12():137-47. PubMed ID: 14224630
    [No Abstract]   [Full Text] [Related]  

  • 19. [Heparin anticoagulant activity: new knowledge and future prospects].
    Camici M; Giusti C; Evangelisti L
    Recenti Prog Med; 1991 Apr; 82(4):209-18. PubMed ID: 1857840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of hirudin on the consumption of antithrombin III in experimental DIC.
    Hauptmann J; Brüggener E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):83-7. PubMed ID: 2459037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.